Terminated, withdrawn and suspended trials

clinicaltrialsObservedShowing 1,651–1,700 of 1,739 studies, most recently updated first

NCT	Title	Phase	Status	First posted	Lead sponsor	Why stopped (as posted)	Category
NCT00128921	Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma	Phase 2	terminated	Aug 10, 2005	University of Arkansas	study terminated due to low accrual	Enrollment / accrual
NCT00704691	Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell…	Early Phase 1	terminated	Jun 25, 2008	University of Alabama at Birmingham	Closed due to futility with only 1 patient accrued	Efficacy / futility
NCT00171925	Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I	Phase 3	terminated	Sep 15, 2005	Novartis Pharmaceuticals	Recruitment in study could not be reached after 8 yrs of recruiting	Enrollment / accrual
NCT00366106	Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple…	Phase 2	terminated	Aug 18, 2006	Accelerated Community Oncology Research Network	Study was closed to enrollment when it became clear that enrollment was too slow to complete full…	Enrollment / accrual
NCT00121186	S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and…	Phase 2	terminated	Jul 21, 2005	SWOG Cancer Research Network	poor accrual	Enrollment / accrual
NCT00827099	Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte…	Phase 2	terminated	Jan 22, 2009	Northside Hospital, Inc.	Unacceptable morbidity \& mortality	Other (stated, no rule matched)
NCT00003929	Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central…	Phase 2	withdrawn	Jul 26, 2004	Case Comprehensive Cancer Center	not stated	Not stated
NCT00402935	Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer	—	withdrawn	Nov 23, 2006	Case Comprehensive Cancer Center	slow accrual	Enrollment / accrual
NCT00389506	Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With…	N/A	withdrawn	Oct 19, 2006	National Institutes of Health Clinical Center (CC)	not stated	Not stated
NCT00488553	Molecular Epidemiology of Lymphoma Patients	—	withdrawn	Jun 20, 2007	M.D. Anderson Cancer Center	No participants recruited, study discontinued.	Enrollment / accrual
NCT01452334	Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy	Phase 1	withdrawn	Oct 14, 2011	Bristol-Myers Squibb	not stated	Not stated
NCT00005969	Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease	Phase 2	withdrawn	Apr 28, 2004	M.D. Anderson Cancer Center	Study withdrawn.	Other (stated, no rule matched)
NCT00475332	Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar	Phase 2	terminated	May 21, 2007	University of Florida	PI left our institution	Investigator
NCT00419081	Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor…	Phase 2	terminated	Jan 8, 2007	BioCryst Pharmaceuticals	Issues with Manufacturing	Drug supply
NCT01175278	Vertebral Augmentation With Kyphoplasty vs Nonsurgical Mgmt for Vertebral Body…	N/A	withdrawn	Aug 4, 2010	H. Lee Moffitt Cancer Center and Research Institute	No enrollment	Enrollment / accrual
NCT00432419	Therapeutic Intensification of HIV-associated Non-Hodgkin's Lymphoma by Peripheral Blood…	Phase 1 / Phase 2	terminated	Feb 7, 2007	French National Agency for Research on AIDS and Viral Hepatitis	only one patient enrolled	Enrollment / accrual
NCT00473551	Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for…	Phase 1	terminated	May 15, 2007	M.D. Anderson Cancer Center	Terminated due to slow accrual.	Enrollment / accrual
NCT00400764	A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other…	Phase 1 / Phase 2	terminated	Nov 17, 2006	Genentech, Inc.	not stated	Not stated
NCT00587015	A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's…	Phase 1	terminated	Jan 7, 2008	MedImmune LLC	Due to a lack of IP supply and then terminated because they were combined into one new study with…	Drug supply
NCT00505921	Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma	Phase 2	terminated	Jul 25, 2007	M.D. Anderson Cancer Center	Slow Accrual.	Enrollment / accrual
NCT00712062	Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System…	Phase 2	withdrawn	Jul 9, 2008	University of Florida	Lack of accrual	Enrollment / accrual
NCT00107614	DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's…	Phase 2	terminated	Apr 6, 2005	University of Arkansas	Terminated due to poor accrual.	Enrollment / accrual
NCT00023790	Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to…	Phase 1	terminated	Jan 27, 2003	Case Comprehensive Cancer Center	slow accrual	Enrollment / accrual
NCT00573391	Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous…	Phase 3	terminated	Dec 14, 2007	University of Arkansas	low accrual	Enrollment / accrual
NCT00880867	Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell…	Phase 1	terminated	Apr 14, 2009	Nevada Cancer Institute	Low enrollment	Enrollment / accrual
NCT00112619	Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia,…	Phase 1	terminated	Jun 3, 2005	Pediatric Brain Tumor Consortium	Slow accrual and company withdrawing support to supply the drug	Drug supply
NCT01116128	Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory…(D-MP)	Phase 2	terminated	May 4, 2010	Fondazione EMN Italy Onlus	difficulty in enrolling patients	Enrollment / accrual
NCT01194193	Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours	Phase 1	withdrawn	Sep 2, 2010	AstraZeneca	Amendment to study compound development programme	Other (stated, no rule matched)
NCT00577668	A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone…	Phase 2	withdrawn	Dec 20, 2007	University of Arkansas	Poor accrual	Enrollment / accrual
NCT00216151	Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple…	Phase 2	terminated	Sep 22, 2005	Hoosier Cancer Research Network	Study terminated due to low patient enrollment.	Enrollment / accrual
NCT01170052	Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell…	Phase 1 / Phase 2	withdrawn	Jul 27, 2010	Charite University, Berlin, Germany	insufficient enrollment	Enrollment / accrual
NCT00813501	Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a…	—	terminated	Dec 23, 2008	City of Hope Medical Center	Terminated at the request of the study sponsor	Other (stated, no rule matched)
NCT00050687	Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various…	Phase 1 / Phase 2	terminated	Dec 19, 2002	Titan Pharmaceuticals	not stated	Not stated
NCT00460460	Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies	Phase 1	terminated	Apr 16, 2007	AstraZeneca	Study was terminated due to low enrollment	Enrollment / accrual
NCT00003113	Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or…	Phase 2	terminated	Sep 24, 2003	Case Comprehensive Cancer Center	not stated	Not stated
NCT00651443	Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular…	Phase 1	terminated	Apr 2, 2008	Biogen	A company's strategic decision to focus on areas whereit believes it can be competitive and decided…	Sponsor / business decision
NCT01116154	Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin…	Phase 1	terminated	May 4, 2010	City of Hope Medical Center	Sponsor withdrew support for the study	Other (stated, no rule matched)
NCT00386321	Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II,…	Phase 2	terminated	Oct 11, 2006	Chulalongkorn University	Participants are no longer being examined or treated.	Other (stated, no rule matched)
NCT00162500	A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies	Phase 2	withdrawn	Sep 13, 2005	Hadassah Medical Organization	not stated	Not stated
NCT00136591	A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell…	Phase 2	terminated	Aug 29, 2005	Lymphoma Study Association	An arm closed due to lack of efficacy	Efficacy / futility
NCT00775957	Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's Lymphoma	—	terminated	Oct 20, 2008	University of Oklahoma	Terminated by institutional review board	Other (stated, no rule matched)
NCT00003567	Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or…	Phase 1	terminated	Jan 27, 2003	Case Comprehensive Cancer Center	slow accrual	Enrollment / accrual
NCT00110006	Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to…	N/A	withdrawn	May 4, 2005	Case Comprehensive Cancer Center	No accrual	Enrollment / accrual
NCT00275262	A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone…	Phase 2	terminated	Jan 11, 2006	Abbott	not stated	Not stated
NCT00298467	MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous…	Phase 2	withdrawn	Mar 2, 2006	Bristol-Myers Squibb	sponsor decision	Sponsor / business decision
NCT00304590	Study of XL999 in Patients With Multiple Myeloma	Phase 2	terminated	Mar 20, 2006	Symphony Evolution, Inc.	Study was terminated due to cardiac toxicities in the subjects	Safety / toxicity
NCT00004058	12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone…	Phase 1	terminated	Jan 27, 2003	University of Medicine and Dentistry of New Jersey	At this time it is felt that we will not gain further information from an additional patients.	Other (stated, no rule matched)
NCT00161239	LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma	N/A	terminated	Sep 12, 2005	University of Medicine and Dentistry of New Jersey	toxicity	Safety / toxicity
NCT00243763	TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma	Phase 1	terminated	Oct 25, 2005	Novartis	not stated	Not stated
NCT00471367	Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877	Phase 1	terminated	May 9, 2007	AstraZeneca	Part B of the study was terminated early due to a lack of enrollment.	Enrollment / accrual

Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.

Data updated 23 days agoSource updated Apr 26, 2012source: clinicaltrials

Terminated, withdrawn and suspended studies

Stated reasons by category

Classification rules